Effects of nicorandil and nifedipine on protection of ischemic myocardium. 1984

K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross

The effects of nicorandil and nifedipine on ischemia--reperfusion-induced myocardial infarct size following a 2-h occlusion and 30-min reperfusion period of the left anterior descending coronary artery (LAD) were compared in anesthetized dogs. Myocardial blood flow was measured using the radioactive microsphere technique, and infarct size was determined using triphenyl tetrazolium chloride histochemical stain. Vehicle, nicorandil (100-micrograms/kg bolus followed by 25 micrograms/kg/min), or nifedipine (10-micrograms/kg bolus followed by 1 microgram/kg/min) was administered intravenously 10 min after LAD occlusion and infused throughout the occlusion and reperfusion periods. Nicorandil and nifedipine reduced mean arterial blood pressure similarly (15 mm Hg) during infusion. However, neither drug altered collateral blood flow to the ischemic region during occlusion. In all three groups, left ventricular mass, area at risk mass, percentage of the left ventricle at risk, and retrograde flow during occlusion were similar. As compared with the control group, nicorandil reduced myocardial infarct size as determined by absolute mass, percentage of the area at risk infarcted, and percentage of the left ventricle infarcted. Nifedipine had no significant effect on infarct size. This beneficial effect of nicorandil was not related to an improvement in myocardial blood flow or a change in global hemodynamics.

UI MeSH Term Description Entries
D008297 Male Males
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
March 1989, European journal of pharmacology,
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
July 1990, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
January 1990, The American journal of cardiovascular pathology,
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
January 1987, Journal of cardiovascular pharmacology,
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
February 1989, The Journal of pharmacology and experimental therapeutics,
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
September 1994, Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao,
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
April 1989, Kokyu to junkan. Respiration & circulation,
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
October 1977, Canadian Medical Association journal,
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
May 1988, Cardiologia (Rome, Italy),
K A Lamping, and C W Christensen, and L R Pelc, and D C Warltier, and G J Gross
January 1973, Transactions of the American Clinical and Climatological Association,
Copied contents to your clipboard!